Scientists test new drug cocktail in fight against aggressive blood cancer
NCT ID NCT05001828
Summary
This study is testing the safety and early effectiveness of adding a new drug, ADI-PEG 20, to a standard two-drug treatment for acute myeloid leukemia (AML). It will involve about 38 adults with either newly diagnosed high-risk AML or AML that has returned after previous treatment. The main goal is to find the safest and most effective dose of the new three-drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.